수의용 수탁제조 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 동물별, 서비스별, 고객별, 지역별 및 부문별 예측(2026-2033년)

Veterinary Contract Manufacturing Market Summary

The global veterinary contract manufacturing market size was estimated at USD 4.0 billion in 2025 and is projected to reach USD 7.7 billion by 2033, growing at a CAGR of 8.6% from 2026 to 2033. The major factors driving growth of the market include rising strategic focus on CMO core business models, increasing capacity expansion & investment in multi-species manufacturing, rising demand for infrastructure development and outsourced manufacturing contracts and favorable regulatory scenario.

The market is driven by companies prioritizing CMO-focused business models to enhance operational efficiency and scalability. Animal health companies are shifting from in-house production to outsourcing, enabling them to focus on R&D, commercialization, and portfolio expansion while leveraging specialized manufacturing expertise. This transition is further supported by growing demand for complex biologics, APIs, and companion animal therapeutics. For instance, in April 2026, Prange Pharma acquired an animal health manufacturing site from MSD Animal Health in Italy, strengthening its contract manufacturing capabilities and strategic positioning in the CDMO space.

In addition, capacity expansion across multi-species manufacturing facilities is a major growth driver, as demand rises for vaccines, APIs, and therapeutics across livestock and companion animals. CDMOs are investing in advanced infrastructure to support diverse production needs, including poultry, swine, and pet healthcare segments. These investments enable flexible, large-scale production while meeting regulatory and quality requirements across geographies. For instance, in September 2025, Sai Life Sciences expanded its dedicated veterinary API manufacturing capacity in India, strengthening its role in global animal health supply chains. Such expansions reflect the industry's shift toward integrated manufacturing platforms capable of handling multiple species and dosage forms, ultimately improving accessibility, reducing costs, and supporting the growing global demand for veterinary products.

Furthermore, the increasing complexity of veterinary pharmaceuticals, including biologics, vaccines, and specialty formulations, is driving demand for outsourced manufacturing services. Some of the companies are depending on CDMOs to access advanced technologies, regulatory expertise, and scalable production without significant capital investment. This trend is particularly evident in emerging markets and niche product segments such as diagnostics and pet therapeutics. For instance, in January 2026, Zomedica entered into a contract manufacturing and services agreement with Rahm Sensor Development to diversify its offerings and expand revenue streams. Such collaborations highlight how outsourcing enables companies to accelerate market entry, optimize costs and enhance product innovation.

Moreover, the market is advancing due to stringent and evolving regulatory frameworks that emphasize product safety, quality, and traceability. Compliance with Good Manufacturing Practices (GMP), biosafety standards, and international guidelines encourages animal health companies to partner with specialized CDMOs possessing regulatory expertise. These partners help navigate complex approval processes across multiple regions, reducing compliance risks and time-to-market. In addition, harmonization efforts and government initiatives to strengthen veterinary oversight are promoting standardized manufacturing practices.

Global Veterinary Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global veterinary contract manufacturing market report based on product, animal, service, customer, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Biologics
  • Vaccines
  • Other Biologics
• Pharmaceuticals
  • Parasiticides
  • Anit-infectives
  • Anti-inflammatory & Analgesics
  • Others Pharmaceuticals
• Nutritional Supplements & Feed Additives
• Medical Devices
• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Production Animals
  • Bovine
  • Poultry
  • Swine
  • Ovine & Caprine
  • Aquaculture
• Companion Animals
  • Dogs
  • Cats
  • Horses
  • Others
• Other Animals
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Manufacturing Services
  • Finished Drug Product Manufacturing
  • Oral Solid Dose (OSD)
  • Oral Liquid Dose
  • Injectables & Sterile Manufacturing
  • Others
  • API Manufacturing
  • Medical Device Manufacturing
• Packaging & Labelling Services
• Other Services
• Customer Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biopharmaceutical Companies
• Animal Feed & Nutrition Companies
• Medical Device Companies
• Other Customer
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Animal
  • 1.2.3. Service
  • 1.2.4. Customer
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information/Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Model 1: Commodity Flow Analysis
  • 1.7.2. Model 2: Bottom-Up Analysis
  • 1.7.3. Model 3 Volume-Pricing Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary/Related Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Strategic Focus On CMO Core Business Models
    • 3.2.1.2. Increasing Capacity Expansion & Investment in Multi-Species Manufacturing
    • 3.2.1.3. Rising Demand for Infrastructure Development and Outsourced Manufacturing Contracts
    • 3.2.1.4. Favorable Regulatory Scenario
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Capital Investment and Infrastructure Requirements
    • 3.2.2.2. Supply Chain Disruptions and Quality Control Challenges
  • 3.2.3. Market Opportunity Analysis
• 3.3. Estimated Animal Population by Key Species & Key Countries, 2025
• 3.4. Pricing Model Analysis
• 3.5. Tariff and Trade Impact Analysis
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL by SWOT Analysis

Chapter 4. Veterinary Contract Manufacturing Market: By Product Estimates & Trend Analysis

• 4.1. Veterinary Contract Manufacturing Market, By Product: Segment Dashboard
• 4.2. Veterinary Contract Manufacturing Market, By Product Movement Analysis
• 4.3. Veterinary Contract Manufacturing Market Estimates & Forecasts, by Product, 2021 to 2033 (USD Million)
• 4.4. Biologics
  • 4.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Vaccines
    • 4.4.2.1. Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Other Biologics
    • 4.4.3.1. Other Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Pharmaceuticals
  • 4.5.1. Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Parasiticides
    • 4.5.2.1. Parasiticides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Anti-infectives
    • 4.5.3.1. Anti-infectives Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Anti-inflammatory & Analgesics
    • 4.5.4.1. Anti-inflammatory & Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.5. Others Pharmaceuticals
    • 4.5.5.1. Others Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Nutritional Supplements & Feed Additives
  • 4.6.1. Nutritional Supplements & Feed Additives Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Medical Devices
  • 4.7.1. Medical Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Veterinary Contract Manufacturing Market: By Animal Estimates & Trend Analysis

• 5.1. Veterinary Contract Manufacturing Market, By Animal: Segment Dashboard
• 5.2. Veterinary Contract Manufacturing Market, By Animal Movement Analysis
• 5.3. Veterinary Contract Manufacturing Market Estimates & Forecasts, by Animal, 2021 to 2033 (USD Million)
• 5.4. Production Animals
  • 5.4.1. Production Animals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Bovine
    • 5.4.2.1. Bovine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Poultry
    • 5.4.3.1. Poultry Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. Swine
    • 5.4.4.1. Swine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.5. Ovine & Caprine
    • 5.4.5.1. Ovine & Caprine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.6. Aquaculture
    • 5.4.6.1. Aquaculture Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Companion Animals
  • 5.5.1. Companion Animals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Dogs
    • 5.5.2.1. Dogs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Cats
    • 5.5.3.1. Cats Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.4. Horses
    • 5.5.4.1. Horses Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.5. Others
    • 5.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Other Animals
  • 5.6.1. Other Animals Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Veterinary Contract Manufacturing Market: By Service Estimates & Trend Analysis

• 6.1. Veterinary Contract Manufacturing Market, By Service: Segment Dashboard
• 6.2. Veterinary Contract Manufacturing Market, By Service Movement Analysis
• 6.3. Veterinary Contract Manufacturing Market Estimates & Forecasts, by Service, 2021 to 2033 (USD Million)
• 6.4. Manufacturing Services
  • 6.4.1. Manufacturing Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. API Manufacturing
    • 6.4.2.2. API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Finished Drug Product Manufacturing
    • 6.4.3.1. Finished Drug Product Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3.2. Oral Solid Dose (OSD)
      • 6.4.3.2.1. Oral Solid Dose (OSD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3.3. Oral Liquid Dose
      • 6.4.3.3.1. Oral Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3.4. Injectables & Sterile Manufacturing
      • 6.4.3.4.1. Injectables & Sterile Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3.5. Others
      • 6.4.3.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Medical Device Manufacturing
    • 6.4.4.1. Medical Device Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Packaging & Labelling Services
  • 6.5.1. Packaging & Labelling Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Other Services
  • 6.6.1. Other Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Veterinary Contract Manufacturing Market: By Customer Estimates & Trend Analysis

• 7.1. Veterinary Contract Manufacturing Market, By Customer: Segment Dashboard
• 7.2. Veterinary Contract Manufacturing Market, By Customer Movement Analysis
• 7.3. Veterinary Contract Manufacturing Market Estimates & Forecasts, by Customer, 2021 to 2033 (USD Million)
• 7.4. Pharmaceutical & Biopharmaceutical Companies
  • 7.4.1. Pharmaceutical & Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Animal Feed & Nutrition Companies
  • 7.5.1. Animal Feed & Nutrition Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Medical Device Companies
  • 7.6.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Other Customer
  • 7.7.1. Other Customer Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Veterinary Contract Manufacturing Market: By Regional Estimates & Trend Analysis

• 8.1. Region Market Dashboard
• 8.2. Region Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Saudi Arabia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Qatar
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Oman
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Aenova Group
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product/Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Grifols International
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product/Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Labiana
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product/Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Argenta Holdco Limited
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product/Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Kela Health
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product/Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Vetio Animal Health
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product/Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. TriRx Pharmaceutical Services
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product/Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Parnell
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product/Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. VetViva Richter GmbH
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product/Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Tecton Industries
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product/Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Ubio Biotechnology Systems Pvt Ltd
    • 9.3.11.1. Participant's Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Product/Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. Terumo Corporation (Terumo BCT)
    • 9.3.12.1. Participant's Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Product/Service Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. BioVenic
    • 9.3.13.1. Participant's Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Product/Service Benchmarking
    • 9.3.13.4. Strategic Initiatives
  • 9.3.14. Esco Aster Pte. Ltd
    • 9.3.14.1. Participant's Overview
    • 9.3.14.2. Financial Performance
    • 9.3.14.3. Product/Service Benchmarking
    • 9.3.14.4. Strategic Initiatives
  • 9.3.15. Alicanto Vetcare
    • 9.3.15.1. Participant's Overview
    • 9.3.15.2. Financial Performance
    • 9.3.15.3. Product/Service Benchmarking
    • 9.3.15.4. Strategic Initiatives